PacBio Announces the HiFi Solves Sub-fertility Consortium in Asia Pacific
The HiFi Solves Sub-fertility Consortium, led by KK Women's and Children's Hospital in Singapore, is leveraging PacBio HiFi long-read sequencing to improve diagnosis and treatment of subfertility and recurrent pregnancy loss (RPL). This collaboration involves five leading centers across the Asia-Pacific region and utilizes DNAstack's federated data platform for secure, efficient global collaboration.
The consortium aims to revolutionize fertility research by offering a more comprehensive and high-resolution approach to identifying complex chromosomal rearrangements and sub-microscopic abnormalities. This initiative is expected to reduce the 'diagnostic odyssey' for patients and enhance the success of assisted reproductive technologies. The project, spanning through 2025, includes patient recruitment, advanced sequencing, and bioinformatics analysis, with the goal of influencing clinical practices globally.
Il Consorzio HiFi per la Sottfertilità, guidato dall'Ospedale KK per le Donne e i Bambini a Singapore, sta utilizzando il sequenziamento a letture lunghe PacBio HiFi per migliorare la diagnosi e il trattamento della sottfertilità e della perdita di gravidanza ricorrente (RPL). Questa collaborazione coinvolge cinque centri leader nella regione Asia-Pacifico e utilizza la piattaforma di dati federati di DNAstack per una collaborazione globale sicura ed efficiente.
Il consorzio mira a rivoluzionare la ricerca sulla fertilità offrendo un approccio più completo e ad alta risoluzione per identificare le complesse riarrangiamenti cromosomici e le anomalie sub-microscopiche. Si prevede che questa iniziativa ridurrà l'odissea diagnostica per i pazienti e migliorerà il successo delle tecnologie di riproduzione assistita. Il progetto, che si estende fino al 2025, comprende il reclutamento di pazienti, sequenziamento avanzato e analisi bioinformatica, con l'obiettivo di influenzare le pratiche cliniche a livello globale.
El Consorcio HiFi para la Subfertilidad, liderado por el Hospital KK de Mujeres y Niños en Singapur, está aprovechando el secuenciación de lecturas largas PacBio HiFi para mejorar el diagnóstico y tratamiento de la subfertilidad y la pérdida recurrente de embarazo (RPL). Esta colaboración involucra a cinco centros líderes en la región de Asia-Pacífico y utiliza la plataforma de datos federados de DNAstack para una colaboración global segura y eficiente.
El consorcio tiene como objetivo revolucionar la investigación sobre la fertilidad, ofreciendo un enfoque más completo y de alta resolución para identificar reordenamientos cromosómicos complejos y anomalías submicroscópicas. Se espera que esta iniciativa reduzca la 'odisea diagnóstica' para los pacientes y mejore el éxito de las tecnologías de reproducción asistida. El proyecto, que se extenderá hasta 2025, incluye el reclutamiento de pacientes, secuenciación avanzada y análisis bioinformático, con el objetivo de influir en las prácticas clínicas a nivel global.
히파이 여성 불임 컨소시엄은 싱가포르 KK 여성 아동 병원이 주도하여 파크바이오 히파이 롱 리드 시퀀싱을 활용하여 불임 진단과 치료 및 반복 임신 손실(RPL)을 개선하고 있습니다. 이 협력은 아시아 태평양 지역의 5개 주요 센터가 참여하며, DNAstack의 연합 데이터 플랫폼을 이용하여 안전하고 효율적인 글로벌 협력을 진행하고 있습니다.
이 컨소시엄은 복잡한 염색체 재배열과 미세한 이상을 파악하기 위해 더 포괄적이고 고해상도 접근 방식을 제공하여 출산 연구를 혁신하는 것을 목표로 하고 있습니다. 이 이니셔티브는 환자의 '진단 여행'을 줄이고 보조생식 기술의 성공률을 높일 것으로 예상됩니다. 이 프로젝트는 2025년까지 진행되며, 환자 모집, 고급 시퀀싱 및 생물정보학 분석을 포함하여, 전 세계적으로 임상 관행에 영향을 미치는 것을 목표로 하고 있습니다.
Le Consortium HiFi sur la Subfertilité, dirigé par l'Hôpital KK pour les Femmes et les Enfants à Singapour, exploite le séquençage à longues lectures PacBio HiFi pour améliorer le diagnostic et le traitement de la subfertilité et de la perte de grossesse récurrente (RPL). Cette collaboration implique cinq centres de premier plan dans la région Asie-Pacifique et utilise la plateforme de données fédérées de DNAstack pour une collaboration globale sécurisée et efficace.
Le consortium vise à révolutionner la recherche sur la fertilité en offrant une approche plus complète et haute résolution pour identifier des réarrangements chromosomiques complexes et des anomalies sub-microscopiques. Cette initiative devrait réduire l' 'odyssée diagnostique' pour les patients et améliorer le succès des technologies de reproduction assistée. Le projet, qui s'étend jusqu'en 2025, inclut le recrutement de patients, le séquençage avancé et l'analyse bioinformatique, avec pour objectif d'influencer les pratiques cliniques à l'échelle mondiale.
Das HiFi Konsortium für Subfruchtbarkeit, geleitet vom KK Frauen- und Kinderkrankenhaus in Singapur, nutzt PacBio HiFi Langlesen-Sequenzierung, um die Diagnose und Behandlung von Subfruchtbarkeit und wiederholtem Schwangerschaftsverlust (RPL) zu verbessern. Diese Zusammenarbeit umfasst fünf führende Zentren in der Asien-Pazifik-Region und verwendet die föderierte Datenplattform von DNAstack für eine sichere und effiziente globale Zusammenarbeit.
Das Konsortium hat sich zum Ziel gesetzt, die Fertilitätsforschung zu revolutionieren, indem es einen umfassenderen und hochauflösenden Ansatz zur Identifizierung komplexer chromosomaler Umstellungen und submikroskopischer Abweichungen bietet. Es wird erwartet, dass diese Initiative die 'diagnostische Odyssee' für Patienten verkürzt und den Erfolg assistierter Fortpflanzungstechnologien erhöht. Das Projekt, das bis 2025 dauert, umfasst die Rekrutierung von Patienten, fortschrittliche Sequenzierung und bioinformatische Analyse, mit dem Ziel, klinische Praktiken weltweit zu beeinflussen.
- Collaboration with five leading centers across Asia-Pacific region
- Utilization of advanced PacBio HiFi long-read sequencing technology
- Potential to improve diagnosis and treatment of subfertility and recurrent pregnancy loss
- Integration of DNAstack's federated data platform for secure global collaboration
- Expected to enhance success of assisted reproductive technologies
- None.
The formation of the HiFi Solves Sub-fertility Consortium marks a significant advancement in fertility research. By leveraging PacBio's HiFi long-read sequencing technology, the consortium aims to revolutionize the diagnosis and treatment of subfertility and recurrent pregnancy loss (RPL). This collaborative effort has the potential to dramatically improve patient outcomes for the
The use of HiFi sequencing offers a more comprehensive and high-resolution approach compared to traditional methods. This could lead to the identification of complex chromosomal rearrangements and sub-microscopic abnormalities often missed by current technologies. The potential for more precise diagnoses could significantly reduce the 'diagnostic odyssey' many patients endure, leading to faster, more effective treatments and improved success rates in assisted reproductive technologies.
The integration of DNAstack's federated data platform in this consortium is a game-changer for genomic research. This platform allows for global collaboration on complex datasets without compromising data security or violating regional data governance policies. In the context of sensitive medical information, this approach ensures that genomic data remains secure while still enabling efficient analysis across borders.
The platform's compliance with standards set by the Global Alliance for Genomics & Health further enhances its credibility and potential for widespread adoption. This technological innovation could serve as a model for future international research collaborations, potentially accelerating breakthroughs in various fields of genomic medicine beyond fertility research.
While this news doesn't directly impact PacBio's immediate financials, it represents a strategic move to expand its market presence in the Asia-Pacific region. The consortium's work could lead to increased adoption of PacBio's HiFi sequencing technology in fertility clinics and research centers across the region. If successful, this could translate to long-term revenue growth for PacBio in a potentially lucrative market.
Moreover, the project's focus on a widespread health issue affecting millions globally could enhance PacBio's reputation as a provider of cutting-edge genomic solutions. This increased visibility and association with breakthrough research could positively impact investor sentiment and potentially lead to new partnership opportunities in other areas of genomic medicine.
Collaboration Aims to Harness HiFi Sequencing to Improve Diagnosis and Treatment of Subfertility and Recurrent Pregnancy Loss
SINGAPORE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The HiFi Solves Sub-fertility Consortium, an innovative collaboration involving five leading centers across the Asia-Pacific region, announces work aimed at redefining the landscape of fertility research. Utilizing PacBio HiFi long-read sequencing, the consortium, led by KK Women's and Children's Hospital (KKH) in Singapore, is pioneering the use of PacBio HiFi long-read sequencing to enhance the diagnosis and treatment of subfertility and recurrent miscarriages (RPL).
The HiFi Solves Sub-fertility Consortium integrates DNAstack’s federated data platform, the world’s first solution to enable the creation and analysis of global federated networks of data in compliance with industry standards set by the Global Alliance for Genomics & Health. This platform allows for seamless global collaboration on complex datasets without the need to move the data, ensuring sensitive genomic information remains secure while supporting efficient analysis and compliance with regional data governance.
Under the leadership of Associate Professor Saumya S. Jamuar, the consortium brings together esteemed experts: Professor Vorasuk Shotelersuk from the Center of Excellence for Medical Genomics, Chulalongkorn University, Thailand; Professor Ming Chen from Changhua Christian Hospital Medical Center, Taiwan; Assistant Professor Jee Soo Lee from Seoul National University College of Medicine (SNUCM) Laboratory Medicine, South Korea; and Associate Professor Sohyun Hwang, CHA Bundang Medical Center, CHA University School of Medicine, South Korea. Together, they are breaking new ground in fertility research with the goal of revolutionizing care for millions affected by subfertility and RPL globally.
“The formation of the HiFi Solves Sub-fertility Consortium is a significant step forward in fertility research,” said Christian Henry, President and Chief Executive Officer of PacBio. “By bringing together leading experts and leveraging the power of HiFi sequencing along with DNAstack’s federated data platform, we are poised to make substantial advancements in the diagnosis and treatment of subfertility and recurrent pregnancy loss.”
Subfertility affects approximately one in six people globally, while RPL impacts 1
This holistic view allows for a more precise characterization of chromosomal changes, particularly beneficial in cases of subfertility and RPL where multiple genetic factors may be involved.
The consortium’s research is poised to significantly reduce the often-frustrating 'diagnostic odyssey' that many patients endure, offering a more streamlined and effective pathway to diagnosis and care. This initiative is expected to greatly enhance the success of assisted reproductive technologies, such as preimplantation genetic testing for structural rearrangements, leading to improved conception rates and healthier pregnancies.
Spanning through the end of 2025, the consortium’s phased approach includes patient recruitment, advanced sequencing, bioinformatics analysis, and rigorous validation of results. Beyond its immediate impact, the consortium aims to influence clinical practices globally, contributing to peer-reviewed publications and presenting breakthroughs at international conferences.
This ambitious project represents a significant leap forward in the application of genomic medicine to reproductive health, with the potential to deliver profound benefits to individuals facing these challenging conditions, underscoring the transformative power of collaborative research and advanced genomic technologies in addressing complex health issues.
For more information, please contact:
Contacts (PacBio)
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
pr@pacificbiosciences.com
Contacts (KKH)
Charlotte Sam
media@kkh.com.sg
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About KK Women's and Children's Hospital (KKH) in Singapore
KK Women’s and Children’s Hospital (KKH) is Singapore’s largest tertiary referral centre for obstetrics, gynaecology, paediatrics and neonatology. The academic medical centre specialises in the management of high-risk conditions in women and children.
Driven by a commitment to deliver compassionate, multidisciplinary care to patients, KKH leverages research and innovation to advance care. In 2021, the hospital launched the SingHealth Duke-NUS Maternal and Child Health Research Institute (MCHRI) to support the growth of every woman and child to their fullest potential, and transform national heath in the region.
Some of the hospital’s breakthroughs include uSINE®, a landmark identification system for the administration of spinal epidural, the discovery of new genetic diseases like Jamuar Syndrome, and a series of guidelines for women and children to improve population health.
The academic medical centre is also a major teaching hospital for Duke-NUS Medical School, Yong Loo Lin School of Medicine and Lee Kong Chian School of Medicine. In addition, KKH runs the largest specialist training programme for Obstetrics and Gynaecology, and Paediatrics in Singapore.
KKH was founded in 1858 and celebrates its 100th year as a maternity hospital in 2024. For more information, visit www.kkh.com.sg
Follow us on
Facebook | Instagram | LinkedIn | TikTok | YouTube
About DNAstack
DNAstack is a Canadian company whose mission is to save and improve lives by unlocking the collective power of the world’s genomics and health data. Omics AI is a software suite by DNAstack that enables privacy-preserving federated insights across distributed data. DNAstack is a global leader in the development of open, interoperable standards as part of the Global Alliance for Genomics & Health (GA4GH).
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including in connection with the HiFi Solves Sub-fertility Consortium research and its efforts to improve the research, diagnosis and treatment of female infertility; efforts to reduce the diagnostic odyssey and enhance the success of assisted reproductive technologies; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in sequencing a large number of genomes, and the difficulty of generating discoveries across various areas of research; potential product performance and quality issues; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with international operations. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
FAQ
What is the goal of the HiFi Solves Sub-fertility Consortium?
How long will the HiFi Solves Sub-fertility Consortium's research project last?
What technology is the HiFi Solves Sub-fertility Consortium using for their research?
How might the HiFi Solves Sub-fertility Consortium's research impact patients?
